A discussion regarding the balance between sensitive versus specific approaches when implementing extended genetic sequencing in cystic fibrosis newborn screening, specifically focusing on the implications of identifying uncertain outcomes (CRMS/CFSPID) compared to the risk of missing actual CF cases.